Drug-Eluting Beads Bronchial Arterial Chemoembolization Combined with Immunotherapy Resulted in Pathological Complete Response of Squamous Cell Lung Cancer: A Case Report

Int Med Case Rep J. 2024 Dec 18:17:1041-1047. doi: 10.2147/IMCRJ.S491862. eCollection 2024.

Abstract

The incidence of lung cancer is the highest among all tumors, and treatment has become an urgent problem to be solved. The Drug-eluting bead-based bronchial arterial chemoembolization (DEB-BACE) combination immunotherapy is a rare neoadjuvant therapy for lung cancer surgery, which can significantly reduce the time it takes for lung cancer patients to undergo surgery.We report a male patient, aged 59-year-old, with Stage-III b squamous cell lung cancer accompanied by hemoptysis underwent surgical resection after DEB-BACE combination immunotherapy treatment 21 days later without obvious adverse events. A pathologic complete response (pCR) was observed postoperatively, and the patient has made a successful recovery. The DEB-BACE combined with immunotherapy might be a new neoadjuvant therapy option for locally advanced non-small cell lung.

Keywords: case report; drug-eluting bead-based bronchial arterial chemoembolization; immunotherapy; squamous cell lung cancer.

Publication types

  • Case Reports

Grants and funding

This work was supported by 2022 Natural Science Foundation of Shandong Province, Project No. ZR2022MH209.